File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Polyfunctional CD8 + T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope

TitlePolyfunctional CD8 + T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope
Authors
KeywordsLiver
Lipopeptide vaccination
Hepatitis C virus
CD8 T cells +
Issue Date2012
Citation
Antiviral Research, 2012, v. 94, n. 2, p. 168-178 How to Cite?
AbstractIn hepatitis C virus (HCV) infection, CD8 + T cell responses have been shown to be important in viral clearance. Examining the efficacy of CD8 + T cell vaccines against HCV has been limited by the lack of an HCV infectious model in mice and the differences between MHC restriction in humans and mice. Using HLA-A2 transgenic HHD mice, we demonstrate that intranasally delivered Pam2Cys-based lipopeptides containing HLA-A2-restricted HCV epitopes can induce polyfunctional CD8 + T cell responses in several organs including the liver. To examine the activity of these responses in an infectious context, we developed a recombinant influenza virus that expresses the NS5B 2594-2602 epitope from non-structural protein 5B of hepatitis C virus (PR8-HCV NS5B). We showed that mice inoculated with a lipopeptide containing the NS5B epitope had reduced viral loads following challenge with the PR8-HCV NS5B virus. This reduction was associated with the induction of NS5B 2594-2602-specific IFN-γ and TNF-α co-producing CD8 + T cells. The T cell receptor usage in the NS5B 2594-2602 response was found to exhibit a Vβ8.1/8.2 bias that was characterized by a narrow repertoire and a common CDR3β motif. This work has identified CD8 + T cell functions induced by lipopeptides that are associated with viral control and demonstrate the potential of lipopeptide-based vaccines as candidates for treatment of HCV infection. © 2012 Elsevier B.V.
Persistent Identifierhttp://hdl.handle.net/10722/241234
ISSN
2015 Impact Factor: 4.909
2015 SCImago Journal Rankings: 2.080

 

DC FieldValueLanguage
dc.contributor.authorTan, Amabel C L-
dc.contributor.authorEriksson, Emily M Y-
dc.contributor.authorKedzierska, Katherine-
dc.contributor.authorDeliyannis, Georgia-
dc.contributor.authorValkenburg, Sophie A.-
dc.contributor.authorZeng, Weiguang-
dc.contributor.authorJackson, David C.-
dc.date.accessioned2017-05-26T03:37:10Z-
dc.date.available2017-05-26T03:37:10Z-
dc.date.issued2012-
dc.identifier.citationAntiviral Research, 2012, v. 94, n. 2, p. 168-178-
dc.identifier.issn0166-3542-
dc.identifier.urihttp://hdl.handle.net/10722/241234-
dc.description.abstractIn hepatitis C virus (HCV) infection, CD8 + T cell responses have been shown to be important in viral clearance. Examining the efficacy of CD8 + T cell vaccines against HCV has been limited by the lack of an HCV infectious model in mice and the differences between MHC restriction in humans and mice. Using HLA-A2 transgenic HHD mice, we demonstrate that intranasally delivered Pam2Cys-based lipopeptides containing HLA-A2-restricted HCV epitopes can induce polyfunctional CD8 + T cell responses in several organs including the liver. To examine the activity of these responses in an infectious context, we developed a recombinant influenza virus that expresses the NS5B 2594-2602 epitope from non-structural protein 5B of hepatitis C virus (PR8-HCV NS5B). We showed that mice inoculated with a lipopeptide containing the NS5B epitope had reduced viral loads following challenge with the PR8-HCV NS5B virus. This reduction was associated with the induction of NS5B 2594-2602-specific IFN-γ and TNF-α co-producing CD8 + T cells. The T cell receptor usage in the NS5B 2594-2602 response was found to exhibit a Vβ8.1/8.2 bias that was characterized by a narrow repertoire and a common CDR3β motif. This work has identified CD8 + T cell functions induced by lipopeptides that are associated with viral control and demonstrate the potential of lipopeptide-based vaccines as candidates for treatment of HCV infection. © 2012 Elsevier B.V.-
dc.languageeng-
dc.relation.ispartofAntiviral Research-
dc.subjectLiver-
dc.subjectLipopeptide vaccination-
dc.subjectHepatitis C virus-
dc.subjectCD8 T cells +-
dc.titlePolyfunctional CD8 + T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.antiviral.2012.03.009-
dc.identifier.pmid22504097-
dc.identifier.scopuseid_2-s2.0-84860297669-
dc.identifier.volume94-
dc.identifier.issue2-
dc.identifier.spage168-
dc.identifier.epage178-
dc.identifier.eissn1872-9096-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats